Congratulations to Madrigal Pharmaceuticals!
We, the undersigned, would like to extend our heartfelt congratulations to Madrigal Pharmaceuticals for achieving FDA approval for Rezdiffra, the first drug to treat metabolic dysfunction-associated steatohepatitis (MASH) in the United States. This monumental step marks a significant advancement in the fight against liver disease and offers hope to millions of patients.
Supportive Commentary:
Your innovative work and dedication to addressing MASH have not gone unnoticed. The approval of Rezdiffra is a beacon of hope for those suffering from this progressive and often undiagnosed condition. With this new therapy, patients now have the opportunity to improve their liver health and overall quality of life.
Call to Action:
As Canadian patients, nurses, physicians, and advocates, we are keenly aware of the pressing need for effective MASH treatments in Canada. It is estimated that about 7% of Canadians suffer from MASH, with many completely unaware of their condition until it progresses to a more severe stage. The incidence of MASH is steadily increasing, and the urgency to provide effective treatment options cannot be overstated.
We respectfully request that Madrigal Pharmaceuticals consider applying to Health Canada to make Rezdiffra available to Canadian patients. By doing so, you will not only extend the benefits of your innovative drug to a broader population but also address a significant unmet medical need in our country. Additionally, we kindly ask our policymakers in the Canadian government to expeditiously move to include new liver treatments in our arsenal of healthcare options for patients.
Our Plea:
This petition calls upon all patients, nurses, physicians and advocates who recognize the critical importance of having access to effective MASH treatments. We believe that every patient deserves the chance to receive the best possible care, and with your help, we can make this a reality for Canadians suffering from MASH.
Together, let's continue the fight against MASH and ensure that Canadian patients have the opportunity to improve their liver health and live healthier lives.
Signatories:
